Limits...
Multi-institutional analysis of T3 subtypes and adjuvant radiotherapy effects in resected T3N0 non-small cell lung cancer patients.

Choi Y, Lee IJ, Lee CY, Cho JH, Choi WH, Yoon HI, Lee YH, Lee CG, Keum KC, Chung KY, Haam SJ, Paik HC, Lee KK, Moon SR, Lee JY, Park KR, Kim YS - Radiat Oncol J (2015)

Bottom Line: In postoperative T3N0M0 patients, the tumor size was a significant prognostic factor for survival (OS, p = 0.035 and DFS, p = 0.035, respectively).However, adjuvant radiotherapy did not cause any improvement in survival (OS, p = 0.518 and DFS, p = 0.463, respectively).Adjuvant radiotherapy is not effective in improving survival outcome in resected T3N0 NSCLC.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiation Oncology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. ; Department of Radiation Oncology, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.

ABSTRACT

Purpose: We evaluated the prognostic significance of T3 subtypes and the role of adjuvant radiotherapy in patients with resected the American Joint Committee on Cancer stage IIB T3N0M0 non-small cell lung cancer (NSCLC).

Materials and methods: T3N0 NSCLC patients who underwent resection from January 1990 to October 2009 (n = 102) were enrolled and categorized into 6 subgroups according to the extent of invasion: parietal pleura chest wall invasion, mediastinal pleural invasion, diaphragm invasion, separated tumor nodules in the same lobe, endobronchial tumor <2 cm distal to the carina, and tumor-associated collapse.

Results: The median overall survival (OS) and disease-free survival (DFS) were 55.3 months and 51.2 months, respectively. In postoperative T3N0M0 patients, the tumor size was a significant prognostic factor for survival (OS, p = 0.035 and DFS, p = 0.035, respectively). Patients with endobronchial tumors within 2 cm of the carina also showed better OS and DFS than those in the other T3 subtypes (p = 0.018 and p = 0.016, respectively). However, adjuvant radiotherapy did not cause any improvement in survival (OS, p = 0.518 and DFS, p = 0.463, respectively). Only patients with mediastinal pleural invasion (n = 25) demonstrated improved OS and DFS after adjuvant radiotherapy (n = 18) (p = 0.012 and p = 0.040, respectively).

Conclusion: The T3N0 NSCLC subtype that showed the most favorable prognosis is the one with endobronchial tumors within 2 cm of the carina. Adjuvant radiotherapy is not effective in improving survival outcome in resected T3N0 NSCLC.

No MeSH data available.


Related in: MedlinePlus

Patterns of failure in resected non-small cell lung cancer T3N0 patients (number of patients).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4493431&req=5

Figure 5: Patterns of failure in resected non-small cell lung cancer T3N0 patients (number of patients).

Mentions: Cancer recurred and/or metastasized during follow-up in 39 patients (38.2%) (Fig. 5). Local recurrence, regional recurrence, and distant metastasis were found in 12 cases (11.8%), 11 cases (10.8%), and 25 cases (24.5%), respectively. The sites of distant metastasis were the brain in 10 patients (9.8%), the contralateral lung in nine patients (8.8%), and bone in eight patients (7.8%).


Multi-institutional analysis of T3 subtypes and adjuvant radiotherapy effects in resected T3N0 non-small cell lung cancer patients.

Choi Y, Lee IJ, Lee CY, Cho JH, Choi WH, Yoon HI, Lee YH, Lee CG, Keum KC, Chung KY, Haam SJ, Paik HC, Lee KK, Moon SR, Lee JY, Park KR, Kim YS - Radiat Oncol J (2015)

Patterns of failure in resected non-small cell lung cancer T3N0 patients (number of patients).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4493431&req=5

Figure 5: Patterns of failure in resected non-small cell lung cancer T3N0 patients (number of patients).
Mentions: Cancer recurred and/or metastasized during follow-up in 39 patients (38.2%) (Fig. 5). Local recurrence, regional recurrence, and distant metastasis were found in 12 cases (11.8%), 11 cases (10.8%), and 25 cases (24.5%), respectively. The sites of distant metastasis were the brain in 10 patients (9.8%), the contralateral lung in nine patients (8.8%), and bone in eight patients (7.8%).

Bottom Line: In postoperative T3N0M0 patients, the tumor size was a significant prognostic factor for survival (OS, p = 0.035 and DFS, p = 0.035, respectively).However, adjuvant radiotherapy did not cause any improvement in survival (OS, p = 0.518 and DFS, p = 0.463, respectively).Adjuvant radiotherapy is not effective in improving survival outcome in resected T3N0 NSCLC.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiation Oncology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. ; Department of Radiation Oncology, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.

ABSTRACT

Purpose: We evaluated the prognostic significance of T3 subtypes and the role of adjuvant radiotherapy in patients with resected the American Joint Committee on Cancer stage IIB T3N0M0 non-small cell lung cancer (NSCLC).

Materials and methods: T3N0 NSCLC patients who underwent resection from January 1990 to October 2009 (n = 102) were enrolled and categorized into 6 subgroups according to the extent of invasion: parietal pleura chest wall invasion, mediastinal pleural invasion, diaphragm invasion, separated tumor nodules in the same lobe, endobronchial tumor <2 cm distal to the carina, and tumor-associated collapse.

Results: The median overall survival (OS) and disease-free survival (DFS) were 55.3 months and 51.2 months, respectively. In postoperative T3N0M0 patients, the tumor size was a significant prognostic factor for survival (OS, p = 0.035 and DFS, p = 0.035, respectively). Patients with endobronchial tumors within 2 cm of the carina also showed better OS and DFS than those in the other T3 subtypes (p = 0.018 and p = 0.016, respectively). However, adjuvant radiotherapy did not cause any improvement in survival (OS, p = 0.518 and DFS, p = 0.463, respectively). Only patients with mediastinal pleural invasion (n = 25) demonstrated improved OS and DFS after adjuvant radiotherapy (n = 18) (p = 0.012 and p = 0.040, respectively).

Conclusion: The T3N0 NSCLC subtype that showed the most favorable prognosis is the one with endobronchial tumors within 2 cm of the carina. Adjuvant radiotherapy is not effective in improving survival outcome in resected T3N0 NSCLC.

No MeSH data available.


Related in: MedlinePlus